The coverage gap in Medicare Part D is not taking as big a bite out of coverage this year as originally expected. But pharma is still nervous about what will happen to patients who do fall in the donut hole. And, though the numbers affected this year may not be as large as feared, pharma comapnies need to learn as much as they can about the impact of the donut hole under Part D.
By Michael McCaughan
September 22 was supposed to be a big day for critics of Medicare Part D. Dubbed "Donut Hole Day" by...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.
The health technology assessment institute, NICE, said the price BioMarin was asking for Brineura was too high, even though its appraisal committee applied a cost-effectiveness threshold ten times higher than usual.
Vertex and Biogen are working with the Dutch government to ensure access for eligible patients.
The arrangement, which implies a behind the scenes negotiated discount, may signal a trend toward less price transparency in foreign markets as manufacturers parry Trump’s Most Favored Nation price demands.
While Japanese government announces 8-15% price cuts for four drugs, including Leqembi, industry groups urge operational improvements to national cost effectiveness assessment scheme.
Returning FDA biologics center director Vinay Prasad used the Papzimeous approval announcement to reinforce his flexibility on rare disease therapies after several complete response letters and his brief departure from the agency.
Enhancing the consistency and clarity of information requests and discipline review letters, and improving assessment milestone communications are key areas targeted by generic drug makers for user fee program negotiations.
